QiShenYiQi pill attenuates atherosclerosis by promoting regulatory T cells, inhibiting T helper 17 cells and accelerating cholesterol excretion

Li Peng; Chong-Shan Lv; Yun Zhao; Shao-Dong Chen; Yang Huang; Da-Wei Lu; Shu-Qiong Huang; Zong-Bao Yang; Lin-Chao Qian; Lei Wen

doi:10.18632/oncotarget.19072

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

QiShenYiQi pill attenuates atherosclerosis by promoting regulatory T cells, inhibiting T helper 17 cells and accelerating cholesterol excretion

Li Peng _, Chong-Shan Lv, Yun Zhao, Shao-Dong Chen, Yang Huang, Da-Wei Lu, Shu-Qiong Huang, Zong-Bao Yang, Lin-Chao Qian and Lei Wen

PDF | HTML | How to cite

Oncotarget. 2017; 8:82196-82206. https://doi.org/10.18632/oncotarget.19072

Metrics: PDF 2452 views | HTML 2937 views | ?

Abstract

Li Peng1, Chong-Shan Lv1, Yun Zhao1, Shao-Dong Chen1, Yang Huang1, Da-Wei Lu1, Shu-Qiong Huang1, Zong-Bao Yang1, Lin-Chao Qian1 and Lei Wen1

1Department of Traditional Chinese Medicine, Medical College, Xiamen University, Xiamen 361102, China

Correspondence to:

Li Peng, email: [email protected]

Lei Wen, email: [email protected]

Keywords: atherosclerosis, regulatory T cell, interleukin-17, cholesterol excretion, QiShenYiQi

Received: March 24, 2017 Accepted: June 05, 2017 Published: July 07, 2017

ABSTRACT

Objective: The aim of this study was to explore potential immunoregulatory mechanisms underlying the suppressive effect on atherosclerosis of QiShenYiQi pill (QSYQ).

Methods and Results: Male ApoE^-/- mice were maintained on a Western-type diet and QSYQ treatment for eight weeks. Determination of atherosclerosis demonstrated that QSYQ attenuated plaque formation and decreased the level of blood low-density lipoproteins-cholesterol. QSYQ treatment did not affect body weight but reduced the ratio of liver weight and body weight. Western blots of liver showed that QSYQ increased the expression of liver X receptor alpha and ATP-binding cassette sub-family G member 5. Western blots of atherosclerotic aorta revealed that QSYQ inhibited the expression of cluster of differentiation 36, promoted the expression of forkhead box P3 and decreased interleukin-17A expression. Western blots of spleen showed that QSYQ decreased the expression of mothers against decapentaplegic homolog 2/3 and forkhead box P3, as well as attenuated the expression of spleen interleukin-6, RAR-related orphan receptor gamma and interleukin-17A.

Conclusions: QSYQ exerted an anti-atherosclerosis effect by promoting regulatory T cells in atherosclerotic lesion, inhibiting T helper 17 cells in plaque and spleen and accelerating liver cholesterol excretion.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19072

Publication Alerts

Research Papers:

QiShenYiQi pill attenuates atherosclerosis by promoting regulatory T cells, inhibiting T helper 17 cells and accelerating cholesterol excretion

Abstract